Houston Methodist Emerging Topics in Liver Disease Conference Innovative Trends in Liver Health 2025
+ Target Audience: hepatologists, transplant surgeons, gastroenterologists, hepatology advanced practice providers
+ Information:
The epidemic of liver disease has become increasingly more common and poses complex problems regarding diagnosis and management. There are recent advances in the diagnosis and management of patients with liver disease. This CE activity has been designed to educate attendees about new developments in hepatology, and new approaches to management of liver diseases that can be readily integrated into their daily practice. A group of national experts, including several renowned guest faculty, will present new findings in a clinical context that will be beneficial in the multidisciplinary management of unique and complex liver disorders.
Target Audience
This conference is designed for primary care physicians, internists, hepatologists, gastroenterologists, oncologists, nurses, nurse practitioners, and physician assistants and other health care providers.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Provide significant information regarding new and critical developments in portal hypertension.
- Identify emerging trends in the Metabolic Dysfunction Associated Fatty Liver Disease (MASLD) and determine the latest concepts in diagnosis and management.
- Explain innovations occurring in the management of liver diseases, including viral hepatitis.
- Discuss current new developments and treatment of liver cancers –an emerging epidemic.
The Houston Methodist Emerging Topics in Liver Disease Conference: Innovative Trends in Liver Health 2025 is best for hepatologists, transplant surgeons, gastroenterologists, hepatology advanced practice providers, hepatology nurses, transplant coordinators, and researchers seeking focused updates on diagnosis, management, and emerging therapies in liver disease.
Who should attend
- Hepatologists and gastroenterologists managing chronic liver disease and complex referrals.
- Transplant surgeons and transplant teams involved in candidate selection, perioperative care, and outcomes.
- Advanced practice providers, nurses, and transplant coordinators delivering multidisciplinary clinical care.
- Clinical researchers and trainees interested in translational advances and new diagnostics or therapeutics.
+ Topics:
| Emerging Topics in Liver Disease Conference: Innovative Trends in Liver Health 2025 | ||
| AGENDA | Saturday, September 20 | ||
| TIME | PRESENTATION | SPEAKER(S) |
| 7:00 AM | Registration & Breakfast | |
| 7:30 AM | Conference Welcome | Victor Ankoma-Sey, MD, FACP, FAASLD |
| 7:40 AM | Introductory Remarks | R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed) |
| PLENARY SESSION I: Unique Complications of Portal Hypertension Moderators: Chukwuma Egwim, MD, Joseph Galati, MD and Ashish Saharia, MD | ||
| 7:50 AM | Drug induced liver injury in the patient with Chronic liver disease | Naga Chalasani, MD |
| 8:20 AM | State of the Art Lecture I Management of Coagulopathy & Bleeding Diathesis in the patient with Cirrhosis | Patrick Northup, MD |
| 8:50 AM | From Risk to Recognition: Addressing Emerging Threats to Improve Prevention and Detection of HCC | Cynthia Ann Moylan, MD, MHS, MS |
| 9:10 AM | Q&A and Discussion | |
| 9:25 AM | BREAK | |
| PLENARY SESSION II: Advances in Metabolic Dysfunction-Associated Fatty liver Disease (MASLD) – What’s New? Moderators: Victor Ankoma-Sey, MD, Tamneet Basra, MD and Constance Mobley, MD | ||
| 9:40 AM | Endocrine Aspects of MASLD & Obesity: 2025 Update | Arun Sanyal, MD |
| 10:10 AM | Noninvasive Assessment of Fibrosis in MASLD | Elliot Tapper, MD |
| 10:40 AM | State of the Art Lecture II Current and Future Treatment Options of MASLD | Manal Abdelmalek, MD |
| 11:10 AM | The patient with MASLD and concomitant Alcohol Associated Liver Disease or HBV or HCV – What to do? | Michelle Jones Pauley, DO , MS |
| 11:30 AM | Q&A and Discussion | |
| 11:45 AM | LUNCH | |
| 11:45 AM | PRODUCT THEATRE (Presented in Boardroom) | Fernando Membreno, MD |
| PLENARY SESSION III: Current Innovations in Liver Disease Moderators: Mark Ghobrial, MD, Caroline Simon, MD & Andrea Duchini, MD | ||
| 12:45 PM | State of the Art Lecture III The Future of Liver transplantation | R. Mark Ghobrial, MD, PhD |
| 1:05 PM | Role of Artificial Intelligence (AI) in the management of liver disease | David Victor III, MD |
| 1:25 PM | Living Donor Liver Transplant – A new Era | Yee Lee Cheah, MD, FACS |
| 1:45 PM | The role of liver transplantation in the management of Cholangiocarcinoma | Ashton Connor, MD |
| 2:15 PM | Q&A and Discussion | |
| 2:30 PM | BREAK | |
| PLENARY SESSION IV: Liver Cancer- Current Concepts Moderators: Sudha Kodali, MD, Julie Corkrean & Julie Luczon | ||
| 2:45 PM | Surveillance & Diagnosis of Hepatocellular Cancer – What is new? | Lewis Roberts, MB, ChB, PHD |
| 3:15 PM | State of the Art Lecture IV Management of Hepatocellular carcinoma- Role of immunotherapy | Ahmed Omar Kaseb, MD, CMQ |
| 3:45 PM | Current and Future Management of Cholangiocarcinoma, a model for personalized Medicine? | Sudha Kodali, MD |
| 4:15 PM | Q&A and Discussion | |
| 4:30 PM | CONCLUDING REMARKS | |



